Balanced news tone
News Sentiment
DXB sentiment intelligence
Dimerix Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
21 relevant articles
News tone and price action are not far from neutral.
85/100 classification confidence.
directly relevant articles
high-authority source matches
+0.0% over one week, +45.5% over four weeks, trend inactive, and below fair value.
Dimerix acquires phase 2-ready kidney injury treatment DMX-652 By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
85/100 classification
One-week reaction
0.0%
Price digesting
Trend fit
Trend inactive
45.5% over four weeks
Fair value
-35.6%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
3
Neutral
18
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Investing.com Australia
Direct company coverage
Dimerix acquires phase 2-ready kidney injury treatment DMX-652 By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 14:51
- Source
- Investing.com Australia
TradingView
Direct company coverage
DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 17 Jul 2026 06:58
- Source
- TradingView
Kalkine
Direct company coverage
Dimerix Limited (ASX:DXB) Shares Rise 4.17% Intraday as the DMX-200 Kidney Story Gathers Momentum
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 04:21
- Source
- Kalkine
Kalkine
Direct company coverage
What Is Fueling Today's Rally in Dimerix (ASX:DXB) Share Price?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 02:44
- Source
- Kalkine
Moomoo
Direct company coverage
Dimerix Acquires Therapeutic Asset From UK-Based Firm; Shares Up 8%
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 02:16
- Source
- Moomoo
Stocks Down Under
Direct company coverage
Dimerix (ASX:DXB) buys DMX-652 and quietly rebuilds its story
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 01:15
- Source
- Stocks Down Under
Kalkine
Direct company coverage
Dimerix (ASX:DXB) Shares Slip: Is the Market Underestimating the Biotechnology Company's Clinical Pipeline?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 07:13
- Source
- Kalkine
Kalkine Media
Direct company coverage
Could Dimerix (ASX:DXB) Be Approaching a Defining Regulatory Phase?
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 10 Jul 2026 04:24
- Source
- Kalkine Media
Kalkine
Direct company coverage
Dimerix (ASX:DXB): Biotech Stock Pullback Puts Clinical Trial Watchers on Alert
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Kalkine
Kalkine
Direct company coverage
Dimerix (ASX:DXB) Debate Builds as Investors Watch the Next Clinical Catalyst
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Kalkine
Kalkine
Direct company coverage
Dimerix (ASX: DXB) Lands Major Asia Deal for DMX-200 Kidney Disease Treatment
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 17 Jun 2026 07:00
- Source
- Kalkine
Kalkine
Direct company coverage
Dimerix (ASX: DXB) Explodes Higher as Biotech Traders Chase Momentum
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Kalkine
BioWorld News
Direct company coverage
Dimerix out-licenses DMX-200 to Everest in AU$481M deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 16 Jun 2026 07:00
- Source
- BioWorld News
The Australian
Direct company coverage
Dimerix inks Asian licensing deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 16 Jun 2026 07:00
- Source
- The Australian
Stockhead
Direct company coverage
Brokers see upside in Dimerix as phase III kidney disease drug trial progresses
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 28 Apr 2026 07:00
- Source
- Stockhead
Kalkine
Direct company coverage
Dimerix (ASX:DXB) Stock Slide Explained: The Key Factors Investors Should Know
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Mar 2026 07:00
- Source
- Kalkine
Kalkine
Direct company coverage
Dimerix (ASX:DXB) Builds Momentum as DMX-200 Advances Through Pivotal Phase 3 Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Mar 2026 07:00
- Source
- Kalkine
The Australian
Direct company coverage
Dimerix doses final patient in Phase III trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Mar 2026 07:00
- Source
- The Australian
BiotechDispatch
Direct company coverage
BioMarin’s acquisition of Amicus adds momentum to Dimerix’s Phase 3 kidney candidate
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 22 Dec 2025 08:00
- Source
- BiotechDispatch
Stockhead
Direct company coverage
Why Dimerix is sparking a major push into Asia-Pacific’s biotech boom
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Dec 2025 08:00
- Source
- Stockhead
smallcaps.com.au
Direct company coverage
Insights: Dimerix Ltd (ASX:DXB)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Oct 2025 13:15
- Source
- smallcaps.com.au